Cargando…

Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials

Bivalirudin has been shown to be safe and efficacious compared with heparin plus glycoprotein IIb/IIIa inhibitor (GPI) in patients undergoing percutaneous coronary intervention (PCI). Whether bivalirudin would have the beneficial effects in female patients undergoing PCI remains unknown. We searched...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Haiyan, Wang, Bingjian, Yang, Jing, Ma, Shuren, Xie, Xiongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241007/ https://www.ncbi.nlm.nih.gov/pubmed/28095453 http://dx.doi.org/10.1371/journal.pone.0169951

Ejemplares similares

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Bivalirudin Anticoagulant Therapy With or Without Platelet Glycoprotein IIb/IIIa Inhibitors During Transcatheter Coronary Interventional Procedures: A Meta-Analysis
por: Li, Jiabei, et al.
Publicado: (2015)

Efficacy and safety of fondaparinux versus enoxaparin in patients undergoing percutaneous coronary intervention treated with the glycoprotein IIb/IIIa inhibitor tirofiban
por: Zhao, Xin, et al.
Publicado: (2016)

Platelet glycoprotein IIb/IIIa inhibitor tirofiban in clopidogrel-naïve patients undergoing elective percutaneous coronary intervention
por: Habibi, Zarina, et al.
Publicado: (2023)

Clinical Benefit of Low Molecular Weight Heparin for ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention with Glycoprotein IIb/IIIa Inhibitor
por: Cho, Jung Sun, et al.
Publicado: (2010)

Influence of glycoprotein IIb/IIIa inhibitors on bleeding events after successful resuscitation and percutaneous coronary intervention
por: Biever, Paul Marc, et al.
Publicado: (2019)

Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019)

Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
por: Suwaidi, Jassim Al, et al.
Publicado: (2001)

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
por: Zeymer, Uwe, et al.
Publicado: (2014)

Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction
por: Howard, J. P., et al.
Publicado: (2014)

Combined glycoprotein IIb/IIIa inhibitor therapy with ticagrelor for patients with acute coronary syndrome
por: Xie, Zhi-Jiang, et al.
Publicado: (2021)

The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
por: Kaluski, Edo
Publicado: (2008)

Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
por: Bavry, Anthony A., et al.
Publicado: (2015)

Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention
por: Centurión, Osmar Antonio
Publicado: (2016)

Platelet Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention: Glycoprotein IIb/IIIa Inhibitors, Clopidogrel, or Both?
por: Silva, Matthew A, et al.
Publicado: (2006)

Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?
por: Iannetta, Loredana, et al.
Publicado: (2013)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
por: Hahn, JongSung, et al.
Publicado: (2023)

Clinical outcomes of bivalirudin versus heparin in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion
por: Zhang, Xiaochun, et al.
Publicado: (2021)

Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis
por: Niu, Xiao-Wei, et al.
Publicado: (2017)

Bivalirudin versus unfractionated heparin: a meta-analysis of patients receiving percutaneous coronary intervention for acute coronary syndromes
por: Farag, Mohamed, et al.
Publicado: (2015)

Efficacy and safety of bivalirudin versus heparin in patients with diabetes mellitus undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Zhang, Juan, et al.
Publicado: (2017)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials
por: Sun, Binjie, et al.
Publicado: (2017)

Absence of platelet membrane glycoproteins IIb/IIIa from monocytes
Publicado: (1985)

A prospective analysis of complications related to the use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes
por: Rocha, RM, et al.
Publicado: (2001)

Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin
por: Centurión, Osmar Antonio
Publicado: (2010)

A meta‐analysis and cost‐minimization analysis of bivalirudin versus heparin in high‐risk patients for percutaneous coronary intervention
por: Sun, Ke‐Xin, et al.
Publicado: (2021)

Effects of Bivalirudin and Unfractionated Heparin on Liver and Renal Function in Chinese Patients with Coronary Artery Disease Undergoing Coronary Angiography with/without Percutaneous Coronary Intervention
por: Jia, Qiaowei, et al.
Publicado: (2021)

The blocking effect of the glycoprotein IIb/IIIa receptor in the mouse model of asthma
por: Kim, Seo-Hee, et al.
Publicado: (2021)

Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
por: Liu, Xiao-Qiang, et al.
Publicado: (2020)

Diffuse alveolar hemorrhage; An under-diagnosed and rare complication of glycoprotein IIb/IIIa inhibitors
por: Hekmat, Hamidreza, et al.
Publicado: (2022)

Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
por: Sim, Doo Sun, et al.
Publicado: (2003)

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
por: Chai, Lina, et al.
Publicado: (2023)

Thrombocytopenia induced by glycoprotein (GP) IIb-IIIa antagonists: about two cases
por: Abdeladim, Salma, et al.
Publicado: (2021)

Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
por: Choi, Woong Gil, et al.
Publicado: (2011)

Distinct Effects of Unfractionated Heparin versus Bivalirudin on Circulating Angiogenic Peptides
por: Kapur, Navin K., et al.
Publicado: (2012)

Bivalirudin versus heparin in primary PCI: clinical outcomes and cost analysis
por: Deharo, Pierre, et al.
Publicado: (2018)

Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials
por: Bhogal, Sukhdeep, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_34355emvm161vjqv3pi4e5v7g1